Immune checkpoint modulators

Relatlimab (anti-LAG-3/CD223) is a human LAG-3 specific monoclonal antibody that binds to LAG-3 on T cells, restoring effector function of exhausted T cells. Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 1.0EU/mg

Relatlimab (anti-LAG-3/CD223) is a human LAG-3 specific monoclonal antibody that binds to LAG-3 on T cells, restoring effector function of exhausted T cells. Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 1.0EU/mg

Relatlimab (anti-LAG-3/CD223) is a human LAG-3 specific monoclonal antibody that binds to LAG-3 on T cells, restoring effector function of exhausted T cells. Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 1.0EU/mg

Retifanlimab (anti-PD-1) is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab (anti-PD-1) can be used for the research of gastroesophageal adenocarcinoma (GEA).

Retifanlimab (anti-PD-1) is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab (anti-PD-1) can be used for the research of gastroesophageal adenocarcinoma (GEA).

Retifanlimab (anti-PD-1) is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab (anti-PD-1) can be used for the research of gastroesophageal adenocarcinoma (GEA).

Retifanlimab (anti-PD-1) is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab (anti-PD-1) can be used for the research of gastroesophageal adenocarcinoma (GEA).

Sugemalimab (anti-PD-L1) is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab (anti-PD-L1) shows anticancer activities and can be used for non-small cell lung cancer

Sugemalimab (anti-PD-L1) is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab (anti-PD-L1) shows anticancer activities and can be used for non-small cell lung cancer

Sugemalimab (anti-PD-L1) is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab (anti-PD-L1) shows anticancer activities and can be used for non-small cell lung cancer

Sugemalimab (anti-PD-L1) is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab (anti-PD-L1) shows anticancer activities and can be used for non-small cell lung cancer

tislelizumab